SHENGUAN HLDGS (00829.HK): Enters Framework Investment Agreement, Proposes RMB 90 Million Collagen Food Production Project

NewTimeSpace News: On 13 August 2026, SHENGUAN HLDGS (00829.HK) announced that its subsidiary Shengguan Biotechnology entered into a framework investment agreement with the Helingeer County government to invest RMB 90 million in a collagen food production project, with a potential acquisition of the use right of an approximately 219-mu industrial plot; if realized, the project is expected to constitute a disclosable transaction, and the land use right has not yet been obtained.

NewTimeSpace News: On 13 August 2026, Shenguan Holdings (Group) Limited (stock code: 00829) announced that its indirect wholly-owned subsidiary, Inner Mongolia Shengguan Biotechnology Co., Ltd., entered into a framework investment agreement with the People's Government of Helingeer County to potentially invest in a collagen food production project in the Horinger Dairy Development Zone, Inner Mongolia. The project's main business scope covers collagen raw material preparation and food processing, as well as the production and sale of edible collagen casings and collagen foods.

The total investment amount is currently estimated at RMB 90 million, including the estimated cost of acquiring the land use right, construction of production facilities, and purchase of machinery and equipment. The proposed site is an approximately 219-mu industrial plot (class I industrial land) north of Haoyuan North Street in the Horinger Dairy Development Zone (subject to the actual land area granted). The acquisition of the land use right is subject to Shengguan Biotechnology's participation in and winning of the bidding/auction for the land, and the Company's full compliance with all applicable disclosure and/or shareholders' approval requirements under the Listing Rules.

The Company stated that the land is adjacent to a major high-quality cattle hide production area, and the project will enhance its medium- and large-caliber collagen casing capacity, reduce raw material logistics costs and support its global strategic layout. If realized, the project is expected to constitute a disclosable transaction under the Listing Rules. The Company also cautioned that the investment agreement is only a framework agreement, that Shengguan Biotechnology has not yet obtained the land use right, and that there is no guarantee that the acquisition or the project will proceed or materialize.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.